Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services. These sessions do not offer CME credit; rather, they give exhibitors the freedom to create a presentation centered on their company’s products. Additional information will be available soon.

Rules and Regulations

Only DDW exhibitors who have secured a booth are eligible to apply for a slot for a product theater, subject to availability and adherence to all published guidelines.

Product Theater

Frequently Asked Questions

Please review the Product Theater FAQ for additional information.

Calendar

  • May 23
  • May 24
  • May 25

Sunday, May 23, 2021

DDW Theater 1 (Hall F)Takeda
Moving Treatment Forward in Chronic Idiopathic Constipation (CIC): A New Option
9:30–10:15 a.m.
This program will discuss the efficacy and safety of a new treatment option for adults with CIC, as well as the unmet need, trial design, mechanism of action and dosing/administration.
EndoGastric Solutions
Shaping the Future of GERD: Now is the Time for TIF 2.0 Procedure
11:30 a.m.–12:15 p.m.
The TIF 2.0 procedure using the EsophyX Z+ device is shaping the future of GRED treatment. Innovators will discuss the latest clinical results and how TIF 2.0 can be used in a broader spectrum of patient populations.
Intercept Pharmaceuticals, Inc
Topics in Advanced Fibrosis due to Nonalcoholic Steatohepatitis (NASH)
1:30–2:15 p.m.
Presented by Dr. Mazen Noureddin, MD MHSc., Director Fatty Liver Program, Division of Digestive and Liver Diseases, Comprehensive Transplant Center, Cedars-Sinai® Medical Center, California.
DDW Theater 2 (Hall B1)Allergan/Ironwood
A Proactive Management Approach to IBS‐C and CIC
10:30–11:15 a.m.
IBS-C and CIC, prevalent disorders with chronic and burdensome symptoms, impacts ~40 million Americans and is associated with a high healthcare system cost. Currently, only 16 million seek care, which leaves many untreated and still suffering. Come to a clinical review of a proactive treatment that may help your patients.
Salix Pharmaceuticals
A Closer Look at Diagnosis, Microbial Imbalance and a Short-Term Treatment Option
12:30–1:15 p.m.
Dr. Ali Rezaie, medical director of the GI motility program at Cedars Sinai Medical Center, Los Angeles, will provide a closer look at IBS-D Diagnosis, Microbial Imbalance and discuss a Short-Term Treatment Option.
Mayo Clinic Laboratories
Early-Onset IBD: Genetic Testing and Its Clinical Application
2:30–3:15 p.m.
Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic for a discussion of this testing and its clinical application.

Monday, May 24, 2021

DDW Theater 1 (Hall F)STERIS | US Endoscopy
Tips, Techniques and Tools for Advanced Polypectomy
9:30–10:15 a.m.
David L. Diehl, MD, FASGE, director of interventional endoscopy, Geisinger Medical Center, Danville, PA, will lead a discussion around tips, techniques and the latest tools for managing flat polyps, defect closure and electrosurgery applications.
Allergan
A Proactive Way to Treat IBS-D: Post-Marketing Information and Phase 4 Data
11:30 a.m.–12:15 p.m.
Please join us in a clinical review of exciting Phase 4 data and the latest post-marketing information on a proactive treatment that may help your IBS-D patients. IBS-D is a chronic functional disorder of the GI system that affects approximately 16 million people and 40% suffers remain undiagnosed.
STERIS | US Endoscopy
Avulsion: A novel technique to achieve complete resection of difficult colon polyps
1:30–2:15 p.m.
Gregory Haber, MD, chief of endoscopy and director of advanced therapeutics and innovation, NYU Langone Medical Center, New York, NY, will lead a discussion around the avulsion technique — using hot biopsy forceps to grasp tissue, apply a mechanical force, while applying bursts of a cutting current with minimal cautery.
DDW Theater 2 (Hall B1)Takeda Pharmaceuticals International
Learn about a treatment option for your patients with moderate to severe Crohn’s Disease (CD) who may be ready to begin a biologic therapy
10:30–11:15 a.m.
In this program, expert gastroenterologist Dr. Brian Feagan will discuss the mechanism of action and clinical profile of a therapeutic option for adult patients with moderate to severe CD who may be ready for a biologic.
Salix Pharmaceuticals
PLENVU: A Novel Bowel Preparation for Patients to Achieve Successful Cleaning
12:30–1:15 p.m.
Dr. Brooks Cash, chief, Division of Gastroenterology, Hepatology & Nutrition, University of Texas Health Science Center at Houston, will be discussing a novel bowel preparation for patients to achieve successful cleaning.
AbbVie
Targeting Disease Activity in UC on the Journey to Remission
2:30–3:15 p.m.
Join us on a journey to find clinical remission featuring real patients with ulcerative colitis from a clinical trial and highlighting the importance of proper induction and optimizing the patient experience.

Tuesday, May 25, 2021

DDW Theater 1Janssen Biotech, Inc.
Janssen Biotech, Inc. Product Theater Presentation
9:30–10:15 a.m.
Speaker: Anita Afali, MD, MPH, FACG
CDx Diagnostics
CDx Diagnostics Product Theater Presentation
11:30 a.m.–12:15 p.m.
Description will be coming soon.

Related Opportunities

DDW Theater

Satellite Symposia

SS provide your organization with a unique opportunity to host educational programs before or after DDW scientific sessions.

In-Conjunction With Meetings

ICWs are meetings and events arranged by exhibitors, third-party planners, educational institutions or other non-profit organizations during DDW.

Reserve Your Booth

Exceed business goals by exposing your company to key decision makers in GI. The Exhibit Hall will be open May 23-25, 2021.